Moffitt Presentations at ASCO 2024
Note - all times are listed as CT
-
Friday, May 31 - Sessions
Melanoma/Skin Cancers
Oral Abstract Session
Zeynep Eroglu (Session Chair, not presenting)
2:45-5:45 p.m.
Hall D1 -
Saturday, June 1 - Sessions and Symposiums
New Frontiers in Lung Cancer Treatment: Expanding Options Beyond Chemoimmunotherapy
Education Session
Ben Creelan
8:15 - 8:30 a.m
Arie Crown TheaterConflicts (of Interest) and Conundrums: Perspectives From the Global Oncology Community
Clinical Science Symposium
Bruna Pellini
1:15 - 2:45 p.m.
S100bc -
Saturday, June 1 - Morning Posters
Abstract TPS9612 - First-in-human study of 225actinium mti-201 (225Ac-MTI-201) in metastatic uveal melanoma (UM).
Poster Board #389b
Nikhil Khushalani
8:00-9:15 a.m.
Hall AAbstract 9543 - High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
Poster Board #327
Ahmad Tarhini
9:00 a.m. - 12:00 p.m.
Hall AAbstract 2621 - A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.
Poster Board #100
Richard Kim
9:00 a.m. - 12:00 p.m.
Hall A
Abstract TPS9611 - A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.
Poster Board #389a
Nikhil Khushalani
9:00 a.m. - 12:00 p.m.
Hall AAbstract 2595 - Phase 1/2 study of XTX202, a tumor-activated IL-2βγ, in advanced solid tumors.
Poster Board #74
Jad Chahoud
9:00 a.m. - 12:00 p.m.
Hall AAbstract 9556 - Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results.
Poster Board #340
Jonathan Zager
9:00 a.m. - 12:00 p.m.
Hall AAbstract 9525 - Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel).
Poster Board #309
Lilit Karapeytan
9:00 a.m. - 12:00 p.m.
Hall AAbstract 9568 - A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits.
Poster Board #352
Ahmad Tarhini
9:00 a.m. - 12:00 p.m.
Hall AAbstract 1525 - Geographic and racial disparities in bi-specific antibodies trials access for diffuse large B-cell lymphoma.
Poster Board #396
Moazzam Shahzad
9:00 a.m. - 12:00 p.m.
Hall A -
Saturday, June 1 - Afternoon Posters
Abstract TPS2090 - A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC).
Poster Board #388b
Peter Forsyth
1:30 - 4:30 p.m.
Hall AAbstract 2030 - Efficacy of intrathecal delivery of peptide-pulsed type 1 conventional dendritic cell vaccine for the treatment of breast cancer-associated leptomeningeal disease in preclinical models.
Poster Board #329
Vincent Law
1:30 - 4:30 p.m.
Hall AAbstract 2032 - Identification of pharmaceutics with selective activity against melanoma-associated leptomeningeal disease using patient-derived circulating tumor cells.
Poster Board #331
Vincent Law
1:30 - 4:30 p.m.
Hall AAbstract 2027 - Tumor reactive T cells from the cerebrospinal fluid of patients with leptomeningeal disease from melanoma.
Poster Board #326
Yolanda Pina
1:30 - 4:30 p.m.
Hall AAbstract 9592 - Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC).
Poster Board #376
Andrew Brohl
1:30 - 4:30 p.m.
Hall AAbstract 3075 - A novel MRI-based tumor-targeting theragnostic agent: Magnetoelectric nanoparticles in an in vivo murine KRAS/P53 pancreatic flank tumor model.
Poster Board #220
John Bryant
1:30 - 4:30 p.m.
Hall A -
Sunday, June 2 - Sessions
Developmental Therapeutics—Immunotherapy
Rapid Oral Abstract Session
Hatem Soliman
11:30 a.m. - 12:45 p.m.
S406Neoadjuvant Approach to Localized Colon Cancer: Ready for Prime Time?
Education Session
Richard Kim
11:30 a.m. - 12:45 p.m.
Arie Crown TheaterUpdates on Novel Therapy for Treatment of TP53-Mutated Myeloid Malignancies
Education Session
David Sallman
11:30 a.m. - 12:45 p.m.
E450bLung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Rapid Oral Abstract Session
Alberto Chiappori
11:30 a.m. - 1:00 p.m.
S406Balancing Hormone Therapy: Minimizing Effects of Androgen Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management
Education Session
Brian Gonzalez
4:30 - 6:00 p.m.
Hall D1 -
Sunday, June 2 - Morning Posters
Abstract TPS1140 - Phase I/II study of stereotactic radiation and sacituzumab govitecan with zimberelimab in the management of metastatic triple negative breast cancer with brain metastases.
Poster Board #108a
Kamran Ahmed
9:00 a.m. - 12:00 p.m.
Hall AAbstract 4600 - Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC).
Poster Board #295
Joshua Minscott
9:00 a.m. - 12:00 p.m.
Hall AAbstract 593 - Evaluating gut microbiome as a biomarker of pathological complete response in patients with early locally advanced triple negative breast cancer (LA TNBC): A pilot study.
Poster Board #185
Humaira Sarfraz
9:00 a.m. - 12:00 p.m.
Hall AAbstract TPS6115 - A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC).
Poster Board #430a
Kedar Kirtane
9:00 a.m. - 12:00 p.m.
Hall AAbstract 4597 - Outcomes of patients with bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer who demonstrated nonresponse to pembrolizumab in KEYNOTE-057: A post hoc analysis.
Poster Board #292
Roger Li
9:00 a.m. - 12:00 p.m.
Hall AAbstract 4601 - Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.
Poster Board #296
Roger Li
9:00 a.m. - 12:00 p.m.
Hall A -
Monday, June 3 - Sessions and Panels
Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.
Oral Abstract Session
Jonathan Strosberg
9:00 a.m. - 12:00 p.m.
E451Multidisciplinary Approach to Navigating Early-Stage Rectal Cancer
Case-Based Panel
Seth Felder (panelist)
1:30 - 4:30 p.m.
Arie Crown Theater -
Monday, June 3 - Posters
Abstract 11148 - Timing of EGFR or ALK inhibitor initiation and survival among patients with advanced NSCLC.
Poster Board #343
Tawee Tanvetyanon
9:00 a.m. - 12:00 p.m.
Hall AAbstract 7524 - Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.
Poster Board #161
Allison Graeter
9:45 - 11:15 a.m.
Hall AAbstract 8545 - A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC).
Poster Board #490
Bruna Pellini
3:00 - 4:00 p.m.
Hall A -
Publication Only
Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma.
Bijal ShahUnveiling the nexus: Use of e-frailty index in predicting chemotherapy tolerance in older patients with pancreatic cancer.
Mohammed Al-JumayliReal-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL).
Sameh GaballaReal-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL.
Javier Pinilla-IbarzDaily diary engagement among caregivers of patients undergoing hematopoietic stem cell transplant.
Ranjita PoudelOn improving clinical trial diversity: Viewpoints from underrepresented breast cancer survivors.
Kimberley LeeGender disparities in Waldenstrom macroglobulinemia: Insights from a comprehensive analysis.
David KaldasEsophageal cancer in the United States: A 21-year mortality analysis (1999-2020).
Muhammad Zain FarooqSafety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT.
Nelli Bejanyan